Clarus Therapeutics Holdings, Inc. (CRXWQ) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Clarus Therapeutics Holdings, Inc. (CRXWQ) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 68/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Clarus Therapeutics Holdings, Inc. (CRXWQ) Resumen de Asistencia Médica y Tuberías
Clarus Therapeutics Holdings, Inc., operating in the pharmaceuticals sector, focuses on men's health with its primary product, JATENZO, an oral testosterone replacement therapy. The company navigated a challenging market landscape, ultimately facing financial difficulties and trading on the OTC market under the ticker CRXWQ.
Tesis de Inversión
Investing in Clarus Therapeutics Holdings, Inc. (CRXWQ) presents significant risks due to its OTC market listing and past financial challenges. The company's primary asset, JATENZO, faces competition and reimbursement hurdles. A potential investment hinges on a successful restructuring or acquisition that unlocks value from its existing assets. Investors should closely monitor the company's financial disclosures, regulatory developments, and any potential strategic partnerships or acquisitions. Given the company's history and current OTC status, a highly speculative approach is warranted.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Gross Margin of 80.5% indicates strong potential profitability if sales volume can be increased.
- Negative Profit Margin of -404.9% highlights significant operational inefficiencies and financial distress.
- JATENZO was the primary product, an oral softgel for testosterone replacement therapy.
- The company faced challenges in securing reimbursement from payers for JATENZO.
- Clarus Therapeutics Holdings, Inc. trades on the OTC market under the ticker CRXWQ.
Fortalezas
- Proprietary oral formulation of testosterone (JATENZO).
- Focus on the men's health market.
- Established relationships with some healthcare providers.
Debilidades
- Financial difficulties and OTC market listing.
- Negative profit margin.
- Limited market share.
- Competition from established players and generic alternatives.
Riesgos
- Ongoing: The company's OTC listing reflects significant financial distress and operational challenges.
- Potential: Limited liquidity in the OTC market can lead to price volatility and difficulty in trading shares.
- Potential: The lack of financial disclosure increases the risk of information asymmetry and potential fraud.
- Potential: Competition from established players and generic alternatives could further erode the company's market share.
- Potential: Regulatory hurdles and reimbursement challenges could hinder the commercialization of its products.
Oportunidades de crecimiento
- Potential Acquisition: Clarus Therapeutics' assets, including JATENZO and related intellectual property, could be acquired by a larger pharmaceutical company seeking to expand its men's health portfolio. The timeline for a potential acquisition is uncertain, but it represents a potential value realization opportunity for current shareholders. The market size for men's health therapies is substantial, making Clarus' assets potentially attractive to strategic acquirers.
- Restructuring and Turnaround: A successful restructuring of Clarus Therapeutics could involve streamlining operations, reducing debt, and focusing on core assets. If the company can achieve operational efficiencies and improve its financial position, it may be able to regain investor confidence and increase its market value. The timeline for a successful turnaround is uncertain and depends on the company's ability to execute its restructuring plan.
- New Product Development: Clarus Therapeutics could explore the development of new products or formulations in the men's health space. This could involve leveraging its existing expertise and infrastructure to create innovative therapies that address unmet needs. The timeline for new product development is typically lengthy and requires significant investment in research and development. However, successful new product launches could drive long-term growth and profitability.
- Strategic Partnerships: Clarus Therapeutics could form strategic partnerships with other pharmaceutical companies or healthcare providers to expand its market reach and access new distribution channels. These partnerships could involve co-marketing agreements, licensing deals, or joint ventures. Strategic partnerships can provide access to new markets and resources, accelerating growth and reducing risk. The timeline for forming strategic partnerships is variable and depends on the availability of suitable partners.
- International Expansion: Clarus Therapeutics could explore opportunities to expand its operations into international markets. This could involve seeking regulatory approvals for JATENZO in other countries and establishing distribution networks to reach new customers. International expansion can significantly increase the company's addressable market and drive revenue growth. However, it also requires significant investment and expertise in navigating foreign regulatory environments and cultural differences.
Oportunidades
- Potential acquisition by a larger pharmaceutical company.
- Successful restructuring and turnaround.
- New product development.
- Strategic partnerships.
- International expansion.
Amenazas
- Competition from established players and generic alternatives.
- Regulatory hurdles.
- Reimbursement challenges.
- Product liability risks.
- Economic downturn.
Ventajas competitivas
- Proprietary formulation of JATENZO (oral softgel testosterone).
- Established relationships with healthcare providers.
- Intellectual property protection for its products.
- Brand recognition in the men's health market.
Acerca de CRXWQ
Clarus Therapeutics Holdings, Inc. was a pharmaceutical company dedicated to the development and commercialization of therapies for men's health. The company's flagship product was JATENZO, an oral softgel formulation of testosterone indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). JATENZO aimed to provide a convenient and effective treatment option for men experiencing low testosterone levels. Founded with the goal of addressing unmet needs in men's health, Clarus Therapeutics sought to differentiate itself through innovative formulations and targeted marketing efforts. The company faced significant challenges in the competitive pharmaceutical market, including navigating regulatory hurdles, securing reimbursement from payers, and effectively marketing its product to healthcare providers and patients. Despite its efforts, Clarus Therapeutics encountered financial difficulties, leading to its current status on the OTC market under the ticker CRXWQ.
Qué hacen
- Developed and commercialized JATENZO, an oral testosterone replacement therapy.
- Focused on addressing unmet needs in men's health.
- Sought regulatory approvals for its products.
- Marketed its products to healthcare providers and patients.
- Navigated the competitive pharmaceutical market.
- Aimed to provide convenient and effective treatment options for men experiencing low testosterone levels.
Modelo de Negocio
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of prescription medications.
- Market products to healthcare providers and patients.
- Seek reimbursement from payers for its products.
Contexto de la Industria
Clarus Therapeutics Holdings, Inc. operated within the competitive pharmaceutical industry, specifically targeting the men's health market. The testosterone replacement therapy market is characterized by established players and generic alternatives. Companies in this space face challenges related to regulatory approvals, marketing, and reimbursement. Market trends include a growing awareness of men's health issues and an increasing demand for convenient and effective treatment options. Clarus Therapeutics aimed to capture a share of this market with JATENZO, but faced competition and financial hurdles.
Clientes Clave
- Adult males diagnosed with hypogonadism (low testosterone).
- Healthcare providers who prescribe testosterone replacement therapy.
- Pharmacies that dispense prescription medications.
- Payers (insurance companies and government healthcare programs) that reimburse for prescription medications.
Finanzas
Gráfico e información
Precio de la acción de Clarus Therapeutics Holdings, Inc. (CRXWQ): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para CRXWQ.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CRXWQ.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CRXWQ.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CRXWQ en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Información del mercado OTC de CRXWQ
The OTC Other tier represents the lowest tier of the OTC market, indicating that Clarus Therapeutics Holdings, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors and may be subject to greater risks. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and less scrutiny, potentially leading to increased volatility and information asymmetry.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases information asymmetry and the risk of fraud.
- Low trading volume and wide bid-ask spreads can lead to significant price volatility.
- The OTC Other tier carries a higher risk of shell company activity and manipulation.
- The company's financial difficulties and past bankruptcy raise concerns about its long-term viability.
- Lack of regulatory oversight increases the potential for mismanagement and corporate governance issues.
- Verify the company's registration and legal standing with the relevant authorities.
- Attempt to obtain and review any available financial statements, even if limited.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other securities.
- Consult with a qualified financial advisor before making any investment decisions.
- Be extremely cautious of any unsolicited investment offers or promotional materials.
- The company previously traded on a major exchange before moving to the OTC market.
- JATENZO was an FDA-approved product, indicating some level of regulatory compliance.
- The company has a history of operations, even if currently distressed.
Acciones de Clarus Therapeutics Holdings, Inc.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar CRXWQ?
Clarus Therapeutics Holdings, Inc. (CRXWQ) actualmente tiene una puntuación IA de 68/100, indicando puntuación moderada. Fortaleza clave: Proprietary oral formulation of testosterone (JATENZO).. Riesgo principal a monitorear: Ongoing: The company's OTC listing reflects significant financial distress and operational challenges.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CRXWQ?
CRXWQ actualmente puntúa 68/100 (Grado B) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CRXWQ?
Los precios de CRXWQ se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CRXWQ?
La cobertura de analistas para CRXWQ incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CRXWQ?
Las categorías de riesgo para CRXWQ incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: The company's OTC listing reflects significant financial distress and operational challenges.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CRXWQ?
La relación P/E para CRXWQ compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CRXWQ sobrevalorada o infravalorada?
Determinar si Clarus Therapeutics Holdings, Inc. (CRXWQ) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CRXWQ?
Clarus Therapeutics Holdings, Inc. (CRXWQ) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is limited due to the company's OTC status and lack of recent filings.
- AI analysis is pending and may provide further insights.